LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

Search

Cencora Inc

Gesloten

SectorGezondheidszorg

361.42 7.68

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

335.63

Max

335.63

Belangrijke statistieken

By Trading Economics

Inkomsten

906M

566M

Verkoop

2.2B

86B

K/W

Sectorgemiddelde

43.265

110.024

EPS

4.08

Dividendrendement

0.64

Winstmarge

0.659

Werknemers

47,000

EBITDA

858M

1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+15.9% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.64%

2.26%

Volgende Winsten

6 mei 2026

Volgende dividenddatum

2 mrt 2026

Volgende Ex Dividend datum

15 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-529M

70B

Vorige openingsprijs

353.74

Vorige sluitingsprijs

361.42

Nieuwssentiment

By Acuity

34%

66%

74 / 351 Rangschikking in Healthcare

Cencora Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 feb 2026, 23:55 UTC

Marktinformatie

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 feb 2026, 23:53 UTC

Marktinformatie

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 feb 2026, 23:53 UTC

Marktinformatie

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 feb 2026, 23:51 UTC

Marktinformatie

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 feb 2026, 23:35 UTC

Marktinformatie

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 feb 2026, 23:21 UTC

Winsten

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 feb 2026, 23:20 UTC

Winsten

Nickel Industries 2025 Operating Profit US$126.4 Million

22 feb 2026, 23:19 UTC

Winsten

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 feb 2026, 23:19 UTC

Winsten

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 feb 2026, 23:18 UTC

Winsten

Nickel Industries Won't Pay a Final Dividend

22 feb 2026, 23:16 UTC

Winsten

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 feb 2026, 21:35 UTC

Winsten

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 feb 2026, 21:34 UTC

Winsten

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 feb 2026, 21:34 UTC

Winsten

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 feb 2026, 21:33 UTC

Winsten

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 feb 2026, 21:33 UTC

Winsten

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 feb 2026, 21:28 UTC

Winsten

Ampol Final Dividend A$0.60/Share

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Revenue A$31.37 Billion, Down 10%

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 feb 2026, 14:31 UTC

Acquisities, Fusies, Overnames

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 feb 2026, 05:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

20 feb 2026, 23:12 UTC

Acquisities, Fusies, Overnames

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Winsten

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Winsten

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Marktinformatie

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Acquisities, Fusies, Overnames

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Marktinformatie

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Peer Vergelijking

Prijswijziging

Cencora Inc Prognose

Koersdoel

By TipRanks

15.9% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 418.5 USD  15.9%

Hoogste 440 USD

Laagste 400 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cencora Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Sentiment

By Acuity

74 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Cencora Inc

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
help-icon Live chat